These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 29562508)

  • 1. PCSK9 Concentrations in Cerebrospinal Fluid Are Not Specifically Increased in Alzheimer's Disease.
    Courtemanche H; Bigot E; Pichelin M; Guyomarch B; Boutoleau-Bretonnière C; Le May C; Derkinderen P; Cariou B
    J Alzheimers Dis; 2018; 62(4):1519-1525. PubMed ID: 29562508
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased PCSK9 Cerebrospinal Fluid Concentrations in Alzheimer's Disease.
    Zimetti F; Caffarra P; Ronda N; Favari E; Adorni MP; Zanotti I; Bernini F; Barocco F; Spallazzi M; Galimberti D; Ricci C; Ruscica M; Corsini A; Ferri N
    J Alzheimers Dis; 2017; 55(1):315-320. PubMed ID: 27662294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cerebrospinal fluid Aβ40 is similarly reduced in patients with Frontotemporal Lobar Degeneration and Alzheimer's Disease.
    Baldeiras I; Santana I; Leitão MJ; Ribeiro MH; Pascoal R; Duro D; Lemos R; Santiago B; Almeida MR; Oliveira CR
    J Neurol Sci; 2015 Nov; 358(1-2):308-16. PubMed ID: 26388316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glial fibrillar acidic protein in the cerebrospinal fluid of Alzheimer's disease, dementia with Lewy bodies, and frontotemporal lobar degeneration.
    Ishiki A; Kamada M; Kawamura Y; Terao C; Shimoda F; Tomita N; Arai H; Furukawa K
    J Neurochem; 2016 Jan; 136(2):258-61. PubMed ID: 26485083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A 2-Step Cerebrospinal Algorithm for the Selection of Frontotemporal Lobar Degeneration Subtypes.
    Lleó A; Irwin DJ; Illán-Gala I; McMillan CT; Wolk DA; Lee EB; Van Deerlin VM; Shaw LM; Trojanowski JQ; Grossman M
    JAMA Neurol; 2018 Jun; 75(6):738-745. PubMed ID: 29554190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cerebrospinal Fluid Biomarkers for the Differential Diagnosis between Alzheimer's Disease and Frontotemporal Lobar Degeneration: Systematic Review, HSROC Analysis, and Confounding Factors.
    Rivero-Santana A; Ferreira D; Perestelo-Pérez L; Westman E; Wahlund LO; Sarría A; Serrano-Aguilar P
    J Alzheimers Dis; 2017; 55(2):625-644. PubMed ID: 27716663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The CSF neurofilament light signature in rapidly progressive neurodegenerative dementias.
    Abu-Rumeileh S; Capellari S; Stanzani-Maserati M; Polischi B; Martinelli P; Caroppo P; Ladogana A; Parchi P
    Alzheimers Res Ther; 2018 Jan; 10(1):3. PubMed ID: 29368621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cognitive impairment in late-life bipolar disorder is not associated with Alzheimer's disease pathological signature in the cerebrospinal fluid.
    Forlenza OV; Aprahamian I; Radanovic M; Talib LL; Camargo MZ; Stella F; Machado-Vieira R; Gattaz WF
    Bipolar Disord; 2016 Feb; 18(1):63-70. PubMed ID: 26876913
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ATN status in amnestic and non-amnestic Alzheimer's disease and frontotemporal lobar degeneration.
    Cousins KAQ; Irwin DJ; Wolk DA; Lee EB; Shaw LMJ; Trojanowski JQ; Da Re F; Gibbons GS; Grossman M; Phillips JS
    Brain; 2020 Jul; 143(7):2295-2311. PubMed ID: 32666090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between β-Secretase, inflammation and core cerebrospinal fluid biomarkers for Alzheimer's disease.
    Alcolea D; Carmona-Iragui M; Suárez-Calvet M; Sánchez-Saudinós MB; Sala I; Antón-Aguirre S; Blesa R; Clarimón J; Fortea J; Lleó A
    J Alzheimers Dis; 2014; 42(1):157-67. PubMed ID: 24820015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort.
    Seeburger JL; Holder DJ; Combrinck M; Joachim C; Laterza O; Tanen M; Dallob A; Chappell D; Snyder K; Flynn M; Simon A; Modur V; Potter WZ; Wilcock G; Savage MJ; Smith AD
    J Alzheimers Dis; 2015; 44(2):525-39. PubMed ID: 25391385
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proprotein convertase subtilisin/kexin type 9 (PCSK9) in Alzheimer's disease: A genetic and proteomic multi-cohort study.
    Picard C; Poirier A; Bélanger S; Labonté A; Auld D; Poirier J;
    PLoS One; 2019; 14(8):e0220254. PubMed ID: 31437157
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cerebrospinal fluid biomarkers in Progranulin mutations carriers.
    Carecchio M; Fenoglio C; Cortini F; Comi C; Benussi L; Ghidoni R; Borroni B; De Riz M; Serpente M; Cantoni C; Franceschi M; Albertini V; Monaco F; Rainero I; Binetti G; Padovani A; Bresolin N; Scarpini E; Galimberti D
    J Alzheimers Dis; 2011; 27(4):781-90. PubMed ID: 21891865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand.
    Thaweepoksomboon J; Senanarong V; Poungvarin N; Chakorn T; Siwasariyanon N; Washirutmangkur L; Udompunthuruk S
    J Med Assoc Thai; 2011 Feb; 94 Suppl 1():S77-83. PubMed ID: 21721431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Decade of Cerebrospinal Fluid Biomarkers for Alzheimer's Disease in Belgium.
    Somers C; Struyfs H; Goossens J; Niemantsverdriet E; Luyckx J; De Roeck N; De Roeck E; De Vil B; Cras P; Martin JJ; De Deyn PP; Bjerke M; Engelborghs S
    J Alzheimers Dis; 2016 Aug; 54(1):383-95. PubMed ID: 27567807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative Genetics Validates Previous Genetic Variants and Identifies Novel Genetic Players Influencing Alzheimer's Disease Cerebrospinal Fluid Biomarkers.
    Ramos de Matos M; Ferreira C; Herukka SK; Soininen H; Janeiro A; Santana I; Baldeiras I; Almeida MR; Lleó A; Dols-Icardo O; Alcolea D; Benussi L; Binetti G; Paterlini A; Ghidoni R; Nacmias B; Meulenbroek O; van Waalwijk van Doorn LJC; Kuiperi HBJ; Hausner L; Waldemar G; Simonsen AH; Tsolaki M; Gkatzima O; Resende de Oliveira C; Verbeek MM; Clarimon J; Hiltunen M; de Mendonça A; Martins M
    J Alzheimers Dis; 2018; 66(2):639-652. PubMed ID: 30320580
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cerebrospinal fluid biomarkers can play a pivotal role in the diagnostic work up of primary progressive aphasia.
    Santangelo R; Coppi E; Ferrari L; Bernasconi MP; Pinto P; Passerini G; Comi G; Magnani G
    J Alzheimers Dis; 2015; 43(4):1429-40. PubMed ID: 25201781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. What are the Most Frequently Impaired Markers of Neurodegeneration in ADNI Subjects?
    Andriuta D; Moullart V; Schraen S; Devendeville A; Meyer ME; Godefroy O;
    J Alzheimers Dis; 2016; 51(3):793-800. PubMed ID: 26923012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between Cerebrospinal Fluid Biomarkers for Alzheimer's Disease, APOE Genotypes and Auditory Verbal Learning Task in Subjective Cognitive Decline, Mild Cognitive Impairment, and Alzheimer's Disease.
    Mandecka M; Budziszewska M; Barczak A; Pepłońska B; Chodakowska-Żebrowska M; Filipek-Gliszczyńska A; Nesteruk M; Styczyńska M; Barcikowska M; Gabryelewicz T
    J Alzheimers Dis; 2016 Jul; 54(1):157-68. PubMed ID: 27472875
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Markers of neuroinflammation associated with Alzheimer's disease pathology in older adults.
    Popp J; Oikonomidi A; Tautvydaitė D; Dayon L; Bacher M; Migliavacca E; Henry H; Kirkland R; Severin I; Wojcik J; Bowman GL
    Brain Behav Immun; 2017 May; 62():203-211. PubMed ID: 28161476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.